ALPHAMAB-B: VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE
ALPHAMAB-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
ALPHAMAB-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
ALPHAMAB-B: VOLUNTARY ANNOUNCEMENT - COLLABORATION WITH ARRIVENT IN RELATION TOTHE RESEARCH, DEVELOPMENT ANDCOMMERCIALIZATION OF ADC PRODUCTS
ALPHAMAB-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
ALPHAMAB-B: VOLUNTARY ANNOUNCEMENT - RESEARCH UPDATES ON A PHASE I/II CLINICAL STUDY OF JSKN003FOR THE TREATMENT OF ADVANCED SOLID TUMORS FORPRESENTATION AT 2024 ASCO ANNUAL MEETING
ALPHAMAB-B: INSIDE INFORMATION ANNOUNCEMENT - UPDATES IN RELATION TO A PHASE III CLINICAL TRIAL OF KN046FOR THE TREATMENT OF ADVANCED PDAC
ALPHAMAB-B: Next Day Disclosure Return
ALPHAMAB-B: VOLUNTARY ANNOUNCEMENT -FIRST PATIENT DOSED IN A PHASE I CLINICAL TRIAL OF JSKN016FOR THE TREATMENT OF ADVANCED MALIGNANT SOLID TUMORS
ALPHAMAB-B: FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ONWEDNESDAY, JUNE 12, 2024
ALPHAMAB-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
ALPHAMAB-B: 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
ALPHAMAB-B: VOLUNTARY ANNOUNCEMENT - UPDATES ON RESULTS OF A PHASE I CLINICAL TRIAL OF JSKN003FOR THE TREATMENT OF HER2-EXPRESSING ADVANCED SOLIDTUMORS FOR PRESENTATION AT 2024 AACR ANNUAL MEETING
ALPHAMAB-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
ALPHAMAB-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
ALPHAMAB-B: Notification Letter to Non-registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
ALPHAMAB-B: Notification Letter to Registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
ALPHAMAB-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
ALPHAMAB-B: VOLUNTARY ANNOUNCEMENT - LICENSE AGREEMENT WITH 3D MEDICINES AND GLENMARK FOR KN035
ALPHAMAB-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
No Data